Bibliographic Details
| Title: |
Age is No Barrier: CAR-T Therapy in Older Adults. |
| Authors: |
Maakaron, Joseph E.1, William, Basem M.2 basemmwilliam@gmail.com |
| Source: |
Drugs & Aging. Aug2023, Vol. 40 Issue 8, p685-689. 5p. |
| Subject Terms: |
*LYMPHOBLASTIC leukemia treatment, *DRUG approval, *B cell lymphoma, *TREATMENT effectiveness, *HEMATOLOGIC malignancies, *T cells, *IMMUNOTHERAPY, *ADULTS, *OLD age |
| Abstract: |
In the last decade, chimeric antigen receptor-T (CAR-T) cells have revolutionized the treatment of hematological malignancies. With six different products for five diseases in various settings, CAR-T use has increased, and the comfort level of prescribers continues to expand. These therapies carry substantial toxicities that may limit their applicability to all patient populations. In the registrational trials, older adults are represented as part of a whole and risks specific to older age may not be clearly outlined. The aim of this review is to summarize the data from clinical trials, as well as real-life evidence, that outline the safety of CAR-T in older adults. With most of the data coming from CD19 CAR-T for diffuse large B-cell lymphoma, it appears that CAR-T can be safely administered to older individuals. [ABSTRACT FROM AUTHOR] |
|
Copyright of Drugs & Aging is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
